The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The chemotherapy-induced peripheral neuropathy (CIPN) market is on the rise, driven by the increasing prevalence of cancer cases worldwide. In 2023, the global CIPN market is projected to reach $1.54 billion, with a compound annual growth rate (CAGR) of 7.12%. This growth is expected to continue, with the market set to reach $2.06 billion in 2027, thanks to several factors, including product innovation and the efforts of major market players.

The Impact of Rising Cancer Cases:
The connection between cancer and chemotherapy-induced peripheral neuropathy treatment market plays a pivotal role in the market’s growth:

• Cancer’s uncontrolled cell growth: Cancer is characterized by the uncontrolled growth and spread of abnormal cells in the body, necessitating chemotherapy.
• CIPN as a side effect: Certain chemotherapy drugs used in cancer treatment can lead to CIPN as a potential side effect.
• A global surge in cancer cases: As per the American Cancer Society’s report, the estimated number of new liver cancer cases in females in the United States increased from 12,660 in 2022 to 13,230 in 2023. This is just one example of the growing cancer prevalence worldwide.

Key Players in the CIPN Treatment Market:
Numerous companies are actively contributing to the expansion of the chemotherapy-induced peripheral neuropathy treatment market:

• Sanofi SA
• Bristol Myers Squibb
• Abbott Laboratories
• Takeda Pharmaceutical Company
• Amgen Inc.
• Asahi Kasei Pharma Corporation
• Toray Industries
• Vertex Pharmaceuticals Inc.
• Alexion Pharmaceuticals Inc.
• BioMérieux SA

Product Innovation:
The Trendsetter Product innovation is driving the chemotherapy-induced peripheral neuropathy treatment market, with major companies actively focusing on developing new and improved products:

• AlgoTx’s groundbreaking approval: In March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, received FDA approval for their Phase 2 candidate, ATX01, for erythromelalgia.
• Fast-track designation: The FDA granted fast-track designation to both the ATX01 program and the “ATX01 for the Pain of Chemotherapy” (ACT) study of CIPN.
• Innovations for better patient outcomes: These innovations aim to enhance patient experiences and improve treatment efficacy.

Segmentation of the CIPN Treatment Market:
The global chemotherapy-induced peripheral neuropathy treatment market is segmented into various categories:

1. By Drug Class:
   • Nerve Protective Therapy
   • Anti-Inflammatory Therapy
   • Neurotransmitter Based Therapy
   • Antioxidant
   • Other Drug Classes
2. By Treatment:
   • Medication
   • Therapy
   • Other Treatments
3. By Drug Type:
   • Branded
   • Generic
4. By Distribution Channel:
   • Hospital Pharmacy
   • Retail Pharmacy
   • Online Pharmacies
   • Other Distribution Channels
5. By End-User:
   • Hospitals
   • Research Institutes
   • Specialty Clinics

Regional Growth Prospects

• North America’s dominance: In 2022, North America held the largest share in the chemotherapy-induced peripheral neuropathy treatment market.
• Rapidly growing regions: Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period.

As the global chemotherapy-induced peripheral neuropathy (CIPN) treatment market continues to expand, it offers hope to cancer patients by providing innovative solutions for CIPN management. The rise in cancer cases worldwide, product innovation, and the active participation of major market players have paved the way for growth in this essential sector of cancer care. With ongoing advancements and a focus on improving patient outcomes, the future of CIPN treatment looks promising.

View More On The Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Request A Sample Of The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=11967&type=smp

The Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2023  provides a comprehensive overview on the chemotherapy induced peripheral neuropathy treatment market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Home Infusion Therapy Global Market Report 2023
Pediatric Neuroblastoma Treatment Global Market Report 2023
Diabetic Neuropathy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model